POZEN Submits NDA for PA32540/PA8140

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transformingmedicine that transforms lives, today announced the submission of a New DrugApplication (NDA) to the U.S. Food and Drug Administration (FDA) for themarketing approval of PA32540/PA8140. Both products are a coordinated-deliverytablet combining immediate-release omeprazole (40 mg), a proton pump inhibitor(PPI), layered around a pH-sensitive coating of an aspirin core. Pendingregulatory approval, an indication is sought for the use of PA tablets for thesecondary prevention of cardiovascular disease in patients at risk foraspirin-induced ulcers.

27% profit every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!